Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.48 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL995920 | 0.80 | HSD17B10 (0.35) | EHMT2EHMT1APOBEC3GL3MBTL1KMT2A | |
| SCHEMBL2423602 | 0.76 | — | — | |
| SCHEMBL301719 | 0.76 | EHMT2 (0.70) | EHMT2EHMT1APOBEC3GL3MBTL1ALDH1A1 | |
| SCHEMBL4280312 | 0.76 | EHMT2 (0.47) | EHMT2EHMT1APOBEC3GL3MBTL1ALDH1A1 | |
| SCHEMBL3145825 | 0.74 | GRM5 (0.33) | — | |
| SCHEMBL10891052 | 0.74 | EHMT2 (0.67) | EHMT2EHMT1APOBEC3GL3MBTL1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28385922 | 0.74 | EHMT2 (0.67) | EHMT2EHMT1APOBEC3GL3MBTL1ALDH1A1 | |
| SCHEMBL1100503 | 0.72 | HPGD (0.57) | L3MBTL1ALDH1A1KMT2ANPSR1GAA | |
| SCHEMBL3145115 | 0.71 | DDAH1 (0.50) | ALDH1A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL4612723 | 0.71 | L3MBTL1 (0.61) | EHMT2EHMT1APOBEC3GL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240074310-A1 | LIGHT-EMITTING DEVICE, AND DISPLAY APPARATUS AND ELECTRONIC APPARATUS INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-02-29 | — | — | US | claimed |
| US-20220216419-A1 | LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-07-07 | — | — | US | claimed |
| CN-113518805-A | Photoinitiator | 意大利艾坚蒙树脂有限公司 | 2021-10-19 | — | — | CN | claimed |
| US-9688645-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2017-06-27 | — | — | US | claimed |
| US-20160251324-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI-AVENTIS (FR) | 2016-09-01 | — | — | US | claimed |
| EP-2226319-B1 | Process for the preparation of 2-(2-aminopyrimidin-4-yl)-1H-indol-5-carbonic acid derivatives | SANOFI SA (FR) | 2016-03-16 | — | — | EP | claimed |
| EP-2520568-B1 | Spirocyclic nitriles as inhibitors of protease | SANOFI SA (FR) | 2015-09-09 | — | — | EP | claimed |
| EP-2240486-B1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINE | SANOFI SA (FR) | 2015-09-09 | — | — | EP | claimed |
| EP-2104497-B1 | SULFAMIDE DERIVATIVES AS TAFIA INHIBITORS | SANOFI SA (FR) | 2015-02-25 | — | — | EP | claimed |
| EP-2558465-B1 | TRICYCLIC PYRIDYL-VINYL-PYROLES AS PAR1 INHIBITORS | SANOFI SA (FR) | 2014-12-17 | — | — | EP | claimed |
| US-20050004166-A1 | Imino acid derivatives as inhibitors of matrix metalloproteinases | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-06 | — | — | US | claimed |
| EP-1474147-A1 | PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2004-11-10 | — | — | EP | claimed |
| WO-2004060874-A1 | IMINO ACID DERIVATIVES FOR USE AS INHIBITORS OF MATRIX METALLOPROTEINASES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-22 | — | — | WO | claimed |
| US-6753415-B2 | BACTERICIDES AGAINST GRAMPOSITIVE AND GRAMNEGATIVE BACTERIA AND MACROLIDE RESISTANT BACTERIA | ENANTA PHARMACEUTICALS, INC. | 2004-06-22 | — | — | US | claimed |
| US-20040077646-A1 | Indole nitriles | ROCHE PALO ALTO LLC | 2004-04-22 | — | — | US | claimed |
| US-20030212010-A1 | 23-O-substituted 5-O-mycaminosyltylonide derivatives | ENANTA PHARMACEUTICALS, INC. | 2003-11-13 | — | — | US | claimed |
| WO-2003089446-A2 | 23-O-SUBSTITUTED 5-O-MYCAMINOSYLTYLONIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| US-20030199526-A1 | Pyrimidine-based compounds useful as GSK-3 inhibitors | VERTEX PHARMACEUTICALS, INCORPORATED | 2003-10-23 | — | — | US | claimed |
| WO-2003049739-A1 | PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS | VERTEX PHARMACEUTICALS, INC. (US) | 2003-06-19 | — | — | WO | claimed |
| US-5696243-A | HEAT AND OXIDATION RESISTANCE | GASF AKTIENGESELLSCHAFT (DE) | 1997-12-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212010-A1 | 23-O-substituted 5-O-mycaminosyltylonide derivatives | OSTC, OGT, O60361 | EHMT2 4852/4885EHMT1 4816/4885APOBEC3G 3315/4885 |
| US-20050004166-A1 | Imino acid derivatives as inhibitors of matrix metalloproteinases | MMP9, MMP1, MMP25 | EHMT2 4432/4885EHMT1 4127/4885APOBEC3G 1237/4885 |
| US-20030199526-A1 | Pyrimidine-based compounds useful as GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | EHMT2 2694/4885EHMT1 2195/4885APOBEC3G 1349/4885 |
| US-20040077646-A1 | Indole nitriles | TPH1, IDO1, NAT1 | EHMT2 3300/4885EHMT1 2007/4885APOBEC3G 2476/4885 |
| US-20160251324-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | TFPI, TFPI2, SERPINC1 | EHMT2 3541/4885EHMT1 3141/4885APOBEC3G 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.